Extremely low frequency electromagnetic fields prevent chemotherapy induced myelotoxicity.
Edoardo Rossi1, Maria Teresa Corsetti, Samir Sukkar
1Department of Haematology, University-Hospital San Martino, Genoa, Italy. edoardo.rossi@hsanmartino.it
Electromagnetic Biology and Medicine
|December 22, 2007
Summary
Chemo-radiotherapy side effects, including fatigue and infections, can be reduced. A novel device using Extremely Low Frequency ElectroMagnetic Fields (ELF-EMF) shows promise in mitigating myelotoxicity in Hodgkin
Area of Science:
- Oncology
- Biophysics
- Medical Devices
Background:
- Chemo-radiotherapy causes significant side effects like fatigue and infections, stemming from myelosuppression, which reduce treatment efficacy and patient survival.
- Late-onset toxicities, including secondary cancers and cardiotoxicity, are also concerns associated with chemo-radiotherapy.
- Oxidative stress is implicated in both the side effects and reduced efficacy of chemo-radiotherapy, suggesting potential benefits from antioxidant interventions.
Purpose of the Study:
- To evaluate the efficacy of SEQEX, an electromedical device generating Extremely Low Frequency ElectroMagnetic Fields (ELF-EMF), in reducing myelotoxicity.
- To assess the impact of ELF-EMF-induced endogenic cyclotronic ionic resonance on patients undergoing the ABVD chemotherapy protocol for Hodgkin's lymphoma.
Main Methods:
- Utilized SEQEX, a device designed to produce Extremely Low Frequency ElectroMagnetic Fields (ELF-EMF).
- The device aims to induce endogenic cyclotronic ionic resonance.
- Application focused on mitigating myelotoxicity in Hodgkin's lymphoma patients receiving the ABVD protocol.
Main Results:
- The study reports experience with the SEQEX device in a clinical setting.
- Observed reduction in myelotoxicity consequent to the ABVD protocol in Hodgkin's lymphoma patients.
- ELF-EMF application demonstrated a potential to mitigate chemotherapy-induced side effects.
Conclusions:
- The electromedical device SEQEX, utilizing ELF-EMF, shows potential in managing chemo-radiotherapy-induced myelotoxicity.
- Endogenic cyclotronic ionic resonance may offer a novel approach to reduce side effects and improve treatment tolerance.
- Further research is warranted to confirm the benefits of ELF-EMF in oncology supportive care.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:14Diamagnetic Shielding of Nuclei: Local Diamagnetic Current
An applied magnetic field causes the electrons present in the molecule to circulate, setting up a local diamagnetic current within the molecule. The local diamagnetic current arising from circulating sigma-bonding electrons induces a magnetic field, Blocal that opposes the applied magnetic field, B0. The effective magnetic field experienced by these nuclei is given by the difference between the applied and local magnetic fields in a phenomenon called local diamagnetic shielding. Essentially,...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...